Arvinas Inc. (NASDAQ:ARVN), a biotechnology company specializing in protein degradation therapeutics, stands at a critical juncture as it approaches the release of pivotal clinical trial data.

Data4Cure today announced an ongoing multi-year partnership with Pfizer, aimed at leveraging advanced analytics and knowledge graph AI to drive innovation in Pfizer’s drug discovery and development ...

Methods Included were studies in any patients, in any healthcare setting where a systems approach was compared with usual care which reported quantitative results ... and data extracted independently ...

Recent research has identified periods when the Federal Reserve intentionally acted to slow inflation when it exceeded ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Ministry of Corporate Affairs (MCA) has introduced funding guidelines for research, workshops, conferences, and similar initiatives under the “Corporate Data Management” scheme. This initiative aims ...

Palantir Technologies’ PLTR outstanding fourth-quarter results, rapid growth amid the artificial intelligence arms race, and ...

Treatment with IV edaravone for ALS was linked to a slowing of disease-progression milestones compared with no IV edaravone ...

EI CoPilot facilitates raw data analysis and results interpretation at rapid speeds, delivering improved accuracy and precision compared to manual processes. This enables the development of AI-powered ...

Short-term use of plant-based meat alternatives could help lower levels of LDL cholesterol and total cholesterol, and help to ...

A daily intake of one gram of omega-3s can slow down biological aging by up to four months, according to an analysis of clinical data from the international DO-HEALTH study. For the first time, ...